<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742326</url>
  </required_header>
  <id_info>
    <org_study_id>080201</org_study_id>
    <nct_id>NCT00742326</nct_id>
  </id_info>
  <brief_title>Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections</brief_title>
  <official_title>Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of pioglitazone in reducing liver fat content in
      patients with HIV and hepatitis C virus (HCV) infections. Fatty liver and accompanying
      insulin resistance in patients with HIV and HCV co-infections is associated with inflammatory
      changes, liver fibrosis and a poorer response to HCV treatment. Pioglitazone is a drug that
      helps to reduce the body's resistance to insulin. It is approved by the Food and Drug
      Administration to treat diabetes.

      Patients with HIV and HCV co-infections who have hepatic steatosis (fatty liver) may be
      eligible for this study. Candidates are screened with a medical history and physical
      examination, blood and urine tests, magnetic resonance imaging (MRI) of the liver to measure
      liver fat and, if needed, a liver biopsy to confirm the diagnosis of liver steatosis.

        -  Participants are randomly assigned to take either pioglitazone therapy or placebo for 48
           weeks. This is followed by a second 48-week treatment period in which all participants
           take pioglitazone.

        -  There are approximately 12 visits during the 96 weeks of the study. Participants will
           receive a physical assessment, blood and urine tests at each visit. In addition,
           periodic assessments of dietary habits, body composition, oral glucose tolerance
           testing, and health related quality of life questionnaires will be completed.

        -  A repeat MRI of the liver is performed at 48 weeks and at the end of the study to
           evaluate any potential changes in liver fat and inflammation. In addition, there is a
           follow-up liver biopsy at 48 weeks and an optional liver biopsy at 96 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following the introduction of effective antiretroviral therapy for HIV, the management of
      co-morbidities such as hepatitis C virus (HCV) has taken on increasing significance in the
      care and health maintenance of chronically infected patients. HCV co-infection is common in
      HIV, with an estimated prevalence of 30 percent among HIV-infected adults in the US. Further,
      the reported prevalence of hepatic steatosis in HIV/HCV co-infection is between 40-67
      percent.

      In recent years, the significance of hepatic steatosis and accompanying insulin resistance in
      HCV has gained increasing recognition. For example, steatosis is associated with increased
      rates of necro-inflammatory change and fibrosis in HIV/HCV co-infected patients. Furthermore,
      studies showed that, among non-HIV infected HCV patients, the presence of steatosis and/or
      insulin resistance was associated with poorer response to HCV therapy. These observations
      have led to research interest in treating hepatic steatosis in HCV, particularly in the
      context of pegylated interferon and ribavirin therapy.

      Administration of the thiazolidinedione, pioglitazone, leads to significant reductions in
      hepatic steatosis, inflammation and in some cases fibrosis in patients with non-alcoholic
      steatohepatitis (NASH). Therefore, the potential benefits of pioglitazone therapy in the
      setting of HIV/HCV co-infection and hepatic steatosis will be determined. The proposed study
      is a 48-week, double-blind, randomized placebo-controlled trial of pioglitazone (45 mg/day)
      in 50 HIV/HCV-infected men and women. After the 48-week randomized portion of the trial, all
      participants will enter a 48-week open treatment extension arm irrespective of original
      randomization. It is anticipated that 100 subjects will be needed to be screened to identify
      a sufficient number of eligible participants to enroll in the study.

      The primary outcome variable of interest in this trial will be the change in hepatic fat
      content measured by magnetic resonance (MR) spectroscopy. Important secondary outcomes will
      be histologic improvement on liver biopsy performed at baseline and 48 weeks, as well as
      improvements in transaminase levels and insulin resistance. The open treatment extension will
      allow all participants an opportunity to receive active study medication and it will allow
      the potential benefits of additional pioglitazone therapy to be assessed. In this way,
      important information about the efficacy of pioglitazone to treat hepatic steatosis and
      improve the metabolic profile in HIV/HCV co-infected patients will be obtained.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment stopped prior to complete enrollment due to slow accrual
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hepatic Steatosis and Hepatic Inflammation/Fibrosis in HIV/HCV Co-infected Patients With Steatosis.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in hepatic steatosis and hepatic inflammation/fibrosis in HIV/HCV co-infected patients with steatosis. Change in Hepatic Fat Content measured by MR spectroscopy: 48 weeks compared to Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Resistance in HIV- and HCV-infected Patients With Steatosis Compared to Placebo</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in Glucose Area Under the Curve from standard oral glucose challenge ( baseline to 2 hours): Week 48 - Baseline values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <condition>Liver Disease</condition>
  <condition>Fatty Liver</condition>
  <condition>Steatosis</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pioglitazone 45 mg daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one capsule daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>45 mg/daily</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one capsule daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Men and women, 18 years of age or greater

        Confirmed HIV infection by ELISA and Western blot

        No changes in antiretroviral regimen within the prior 3 months--Individuals not currently
        taking antiretroviral therapy will be eligible. Individuals requiring medically indicated
        adjustments of antiretroviral therapy during the course of the study will be eligible.

        Confirmed HCV infection, and no current or recent (within the past 3 months) HCV treatment
        and no plans to start HCV antiviral therapy in the foreseeable future.

        H-MRS liver fat content greater than 5 percent and confirmed steatosis on liver biopsy
        within 1 year

        Fasting glucose less than 126 mg/dL

        Platelets greater than or equal to 75,000/uL; INR less than 1.6

        Willingness to avoid medications and herbal supplements which may increase the risk of
        bleeding for one week prior to and one week following liver biopsy (e.g. aspirin,
        nonsteroidal anti-inflammatory drugs (NSAIDs), Vitamin E, fish oil and gingko biloba).

        Willingness to restrict physical activity 72 hours after liver biopsy

        If premenopausal female, willingness to use 2 forms of effective birth control on this
        study to avoid pregnancy.

        Have a primary care physician

        Willingness to have specimens stored.

        EXCLUSION CRITERIA:

        Current thiazolidinedione use or use in the last 6 months, known allergy or sensitivity to
        a thiazolidinedione

        Use of insulin or other oral hypoglycemics, or known diabetes

        Current pregnancy, breast feeding, or pregnancy within the past 6 months or desire to
        become pregnant within the next 2 years.

        Child-Pugh-Turcotte (CPT) score greater than class A

        ALT greater than 4 times the upper limit of normal

        Current or history of heart failure (New York Heart Association [NYHA] Class III or IV
        cardiac status)

        Hemoglobin level less than 9g/dL

        Active or ongoing infection with Hepatitis A or B

        Known or suspected liver disease such as autoimmune hepatitis, Wilson's disease,
        alpha-1-antitrypsin deficiency, cystic fibrosis, hemochromatosis, glycogen storage disease,
        amyloidosis, primary biliary cirrhosis, sclerosing cholangitis, or any primary or secondary
        hepatic tumor

        Current alcohol/substance abuse

        Use of growth hormone, prednisone or other anabolic agents (except for physiologic
        testosterone replacement) currently or within the past 3 months. One day or less of
        corticosteroid within the prior 90 days of screening is allowed as is stable dose
        inhalation corticosteroids

        Concurrent use of ketoconazole

        Active opportunistic infection (except thrush) or neoplasm (except Kaposi's sarcoma, skin
        cancer, cancer of the cervix or anus)

        Any known contraindications to percutaneous liver biopsy including elevated PT/PTT

        Severe psychiatric illness that would interfere with adherence to protocol requirements

        Current treatment with interleukin-2, interferon-alpha, or other investigational agent(s)
        within the past 6 months (This does not pertain to ARVs obtained through expanded access)

        Any significant medical condition for which the investigator believes a liver biopsy or
        participation in the research protocol may be contraindicated

        Any contraindication to MRI scan, including excess body size
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen M Hadigan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jain MK, Skiest DJ, Cloud JW, Jain CL, Burns D, Berggren RE. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis. 2003 Apr 15;36(8):1030-8. Epub 2003 Apr 2.</citation>
    <PMID>12684916</PMID>
  </reference>
  <reference>
    <citation>Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000 Apr;30 Suppl 1:S77-84. Review.</citation>
    <PMID>10770916</PMID>
  </reference>
  <reference>
    <citation>Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005 Mar 24;19(6):585-92.</citation>
    <PMID>15802977</PMID>
  </reference>
  <reference>
    <citation>Matthews L, Kleiner DE, Chairez C, McManus M, Nettles MJ, Zemanick K, Morse CG, Benator D, Kovacs JA, Hadigan C. Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. AIDS Res Hum Retroviruses. 2015 Oct;31(10):961-6. doi: 10.1089/AID.2015.0093. Epub 2015 Aug 24.</citation>
    <PMID>26214341</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <results_first_submitted>April 10, 2014</results_first_submitted>
  <results_first_submitted_qc>May 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2014</results_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Liver Disease</keyword>
  <keyword>Fatty Liver</keyword>
  <keyword>Steatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Decision will be made at the time of request</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone</title>
          <description>pioglitazone 45 mg daily for 48 weeks
Pioglitazone</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo once daily for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone</title>
          <description>pioglitazone 45 mg daily for 48 weeks
Pioglitazone</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo once daily for 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="5"/>
                    <measurement group_id="B2" value="53" spread="6"/>
                    <measurement group_id="B3" value="52" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hepatic Steatosis and Hepatic Inflammation/Fibrosis in HIV/HCV Co-infected Patients With Steatosis.</title>
        <description>Change in hepatic steatosis and hepatic inflammation/fibrosis in HIV/HCV co-infected patients with steatosis. Change in Hepatic Fat Content measured by MR spectroscopy: 48 weeks compared to Baseline</description>
        <time_frame>48 weeks</time_frame>
        <population>Two subjects (one in each group) did not have a follow up MRI for comparision to baseline. One developed claustrophobia and could not tolerate MRI and one was discontinued from study due to other illnesses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>pioglitazone 45 mg daily for 48 weeks
Pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hepatic Steatosis and Hepatic Inflammation/Fibrosis in HIV/HCV Co-infected Patients With Steatosis.</title>
          <description>Change in hepatic steatosis and hepatic inflammation/fibrosis in HIV/HCV co-infected patients with steatosis. Change in Hepatic Fat Content measured by MR spectroscopy: 48 weeks compared to Baseline</description>
          <population>Two subjects (one in each group) did not have a follow up MRI for comparision to baseline. One developed claustrophobia and could not tolerate MRI and one was discontinued from study due to other illnesses.</population>
          <units>percentage of hepatic fat on MRS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.43" spread="4.6"/>
                    <measurement group_id="O2" value="-2.17" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Resistance in HIV- and HCV-infected Patients With Steatosis Compared to Placebo</title>
        <description>Change in Glucose Area Under the Curve from standard oral glucose challenge ( baseline to 2 hours): Week 48 - Baseline values</description>
        <time_frame>48 weeks</time_frame>
        <population>One subject in the placebo arm was discontinued due to health issues and does not have a 48 week OGTT available</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>pioglitazone 45 mg daily for 48 weeks
Pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Resistance in HIV- and HCV-infected Patients With Steatosis Compared to Placebo</title>
          <description>Change in Glucose Area Under the Curve from standard oral glucose challenge ( baseline to 2 hours): Week 48 - Baseline values</description>
          <population>One subject in the placebo arm was discontinued due to health issues and does not have a 48 week OGTT available</population>
          <units>mg*120 minutes/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31" spread="29.2"/>
                    <measurement group_id="O2" value="11" spread="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks of randomized study participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone</title>
          <description>pioglitazone 45 mg daily for 48 weeks
Pioglitazone</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo once daily for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Protocol Tox Table</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dental Abscess</sub_title>
                <description>Dental abscess requiring treatment related to poor dentition</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung Cancer</sub_title>
                <description>Patient was diagnosed with advanced stage lung cancer during study participation. Participation in the study was discontinued by the study team when the diagnosis was made.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Insufficiency</sub_title>
                <description>Renal insufficiency identified, related to HIV antiretroviral therapy. Resolved after changing antiretroviral mediactions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Protocol Tox Table</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Increased cholesterol</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Decrease serum albumin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study failed to enroll to the originally established sample size due to slow enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Colleen Hadigan MD MPH</name_or_title>
      <organization>NIAID</organization>
      <phone>301-594-5754</phone>
      <email>hadiganc@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

